Stock ABLI ABLIVA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Abliva AB

Equities

ABLI

SE0002575340

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:55 2024-04-26 am EDT 		5-day change 1st Jan Change
0.1648 SEK +1.10% Intraday chart for Abliva AB +3.26% -32.87%
Feb. 23 Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
2023 Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 126.5 249.2 226.7 240.8 189.1 259.3 222.4 -
Enterprise Value (EV) 1 100.6 190.9 226.7 218.5 189.1 259.3 98.38 49.38
P/E ratio -1.47 x -2.98 x -3.19 x -1.81 x -1.49 x -2.73 x -1.27 x -1.1 x
Yield - - - - - - - -
Capitalization / Revenue 25,308 x 1,860 x 122 x 1,595 x - - - -
EV / Revenue 20,118 x 1,424 x 122 x 1,447 x - - - -
EV / EBITDA -1.47 x -2.56 x -3.94 x -1.81 x - - -0.71 x -0.32 x
EV / FCF -1.49 x - - - - - -0.73 x -0.33 x
FCF Yield -67.3% - - - - - -136% -306%
Price to Book - - - - - - 1.37 x 1.03 x
Nbr of stocks (in thousands) 91,697 185,953 296,340 403,007 1,056,299 1,056,299 1,349,385 -
Reference price 2 1.380 1.340 0.7650 0.5975 0.1790 0.2455 0.1648 0.1648
Announcement Date 2/28/19 2/19/20 2/19/21 4/29/22 2/24/23 2/23/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 0.005 0.134 1.864 0.151 - - - -
EBITDA 1 -68.59 -74.7 -57.51 -120.7 - - -139 -154
EBIT 1 -73.36 -77.07 -60.07 -123.5 - - -142 -157
Operating Margin -1,467,200% -57,517.91% -3,222.69% -81,776.16% - - - -
Earnings before Tax (EBT) 1 -73.49 -77 -59.99 -123.5 - - -142 -157
Net income 1 -68.37 -76.99 -59.99 -123.5 -85.26 -95.51 -142 -157
Net margin -1,367,460% -57,458.21% -3,218.56% -81,786.75% - - - -
EPS 2 -0.9400 -0.4500 -0.2400 -0.3300 -0.1200 -0.0900 -0.1300 -0.1500
Free Cash Flow 1 -67.7 - - - - - -134 -151
FCF margin -1,354,020% - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/28/19 2/19/20 2/19/21 4/29/22 2/24/23 2/23/24 - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - - -
Net Cash position 1 26 58.3 - 22.3 - - 124 173
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -67.7 - - - - - -134 -151
ROE (net income / shareholders' equity) -69.2% - - - - - - -
ROA (Net income/ Total Assets) -58.1% - - - - - - -
Assets 1 117.7 - - - - - - -
Book Value Per Share 2 - - - - - - 0.1200 0.1600
Cash Flow per Share - - - - - - - -
Capex 1 0.08 0.07 - - - - 1 1
Capex / Sales 1,640% 51.49% - - - - - -
Announcement Date 2/28/19 2/19/20 2/19/21 4/29/22 2/24/23 2/23/24 - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ABLIVA AB Stock Abliva AB
-32.87% 20.28M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ABLI Stock
  4. Financials Abliva AB